Dalfaz retard pills p \ about 5mg №56

Mechanism of action

Blocker alpha1-adrenoreceptors (mainly in the area of ​​the prostate gland, urethra and triangle of the bladder). It reduces the pressure in the urethra and reduces the resistance to the flow of urine, facilitates urination and eliminates dysuria, including with prostatic hyperplasia. In therapeutic doses, does not affect the alpha1-adrenergic receptors of blood vessels.

After ingestion of 5 mg Cmax (10.3 ng / ml) in plasma is achieved after 3 hours. Bioavailability is 45-53%. Eating does not affect the absorption of the active substance. Communication with plasma proteins - 90%. T1 / 2 - 8 h. Metabolized in the liver. It is excreted mainly with bile and with feces (75-91%) in the form of inactive metabolites and the kidneys in the form of inactive metabolites (15-30%) and unchanged (11%). In older people, absorption is faster, Cmax and bioavailability are higher, the volume of distribution is lower, T1 / 2 remains unchanged. In CRF, the volume of distribution and the total clearance increase as a result of a decrease in the degree of binding to plasma proteins. Due to a high degree of metabolism, even with severe CRF (CC - 15–40 ml / min), cumulation does not occur. In chronic heart failure, pharmacokinetic parameters do not change.

Indications and usage

Functional disorders of urination with benign prostatic hyperplasia.

Inside, without chewing, on 5 mg in the morning and in the evening, to begin treatment with evening reception. Daily dose - 10 mg. Elderly and patients receiving antihypertensive therapy, administered at 5 mg / day, in the evening, if necessary, increase the dose to 10 mg / day (no more).

Adverse reactions

On the part of the digestive system: dry mouth, nausea, diarrhea, epigastric pain, diarrhea. From the nervous system: headache, dizziness, weakness, drowsiness, asthenic syndrome. From the CCC side: tachycardia, orthostatic hypotension, in patients with coronary artery disease - exacerbation of symptoms of angina pectoris. Allergic reactions: skin rash, itching. Other: tinnitus, edema, skin flushing.Overdose. Symptoms: decreased blood pressure. Treatment: the introduction of vasoconstrictor drugs, solutions of high-molecular substances, an increase in the BCC, dialysis - is ineffective.

Contraindications

Hypersensitivity, orthostatic hypotension (in history), the simultaneous reception of other alpha-blockers. With care: ischemic heart disease, chronic renal failure, concomitant therapy with antihypertensives, old age (over 75 years).

Not compatible with other alpha1-blockers. Enhances the effect of antihypertensive drugs, incl. BMCC and general anesthetics (possible instability of blood pressure during anesthesia).